As Bayer Stock Cools From Rally Highs, Barclays Sees 25% Upside and Amundi Quietly Crosses a Key Threshold
Published on 07/16/2026 at 11:02 | Redaktion boerse-global.de
The weeks following a sharp rally often deliver mixed signals, and Bayer’s current phase is no exception. While the shares have pulled back from their 52-week peak, two separate developments this week — a bullish analyst call and a regulatory disclosure from a major asset manager — tug the narrative in opposite directions, setting the stage for a pivotal August reporting date.
The stock edged down 0.65% on Thursday to €47.36, extending a consolidation that began after a blistering 30-day run of nearly 33%. On 3 July, Bayer touched a 52-week high of €53.86, but profit-taking has since shaved roughly 12% off that level. The move is widely viewed as a natural breather — the RSI sits at a moderate 56.7, well below overbought territory, and the 200-day moving average of €38.00 remains comfortably underneath, preserving the medium-term uptrend. Annualised 30-day volatility of around 62% suggests the calmer patch may still see sharp daily swings.
Into this quiet period — which Bayer entered on 15 July, meaning management will not comment on business developments until the half-year report — came a mandatory disclosure from Paris-based asset manager Amundi S.A. On 8 July, the firm crossed the 3% voting-rights threshold, pushing its Bayer stake from 2.99% to 3.09%. The filing, published on 14 July, revealed that Amundi controls 30,375,174 shares indirectly through a network of subsidiaries across multiple jurisdictions, along with 13,770 voting rights from lent securities. With Bayer’s total voting rights at roughly 982.4 million, the move is a purely structural signal — it alters the shareholder register without any operational implication for the group.
Should investors sell immediately? Or is it worth buying Bayer?
The same day, Barclays analyst Charles Pitman-King lifted his price target on Bayer from €50 to €60, maintaining an “Overweight” rating. The 25% implied upside from current levels rests on a stark reassessment of US legal risks. In late June, the US Supreme Court significantly weakened the basis for thousands of glyphosate-related lawsuits. While final approval of the negotiated settlement is still pending, Barclays sees a decisive improvement in the risk-reward calculus. Better agricultural chemical prospects for the second half of the year add further fuel to the upgrade.
Investor attention this week also shifted toward Bayer’s venture arm, Leaps by Bayer, which led an oversubscribed Series B funding round for US ag-tech company Sabanto. The autonomous farming specialist plans to use the capital to accelerate market penetration of its technology, expand its customer base, and scale retrofit autonomy kits across North America. Other participants included Sustainable Forward Capital, DCVC, and Yara. Leaps by Bayer has now invested over $2.1 billion in more than 65 healthcare and agriculture companies.
With the quiet period in force until the half-year report on 4 August, the near-term direction hinges on analyst commentary and broader DAX sentiment. The Barclays upgrade provides a bullish anchor, while the Amundi filing underlines that institutional interest remains strong even as the stock takes a breather. When Bayer finally lifts the lid on its second-quarter numbers, investors will be watching debt repayment, cash flow, and the impact of the minority stake sale to Apollo in its long-acting contraceptive business — a set of numbers that will test whether the rally’s foundation is as solid as the technicals suggest.
Ad
Bayer Stock: New Analysis - 16 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
